Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

被引：10

作者：

Antonia, Scott ^{[1
]}

Rizvi, Naiyer ^{[2
]}

Brahmer, Julie ^{[3
]}

Ou, Sai-Hong ^{[4
]}

Khleif, Samir N. ^{[5
]}

Hwu, Wen-Jen ^{[6
]}

Gutierrez, Martin ^{[7
]}

Schoffski, Patrick ^{[8
]}

Hamid, Omid ^{[9
]}

Weiss, Jared ^{[10
]}

Lutzky, Jose ^{[11
]}

Maio, Michele ^{[12
]}

Nemunaitis, John ^{[13
]}

Jaeger, Dirk ^{[14
]}

Balmanoukian, Ani ^{[9
]}

Rebelatto, Marlon C. ^{[15
]}

Steele, Keith E. ^{[15
]}

Jin, Xiaoping ^{[15
]}

Robbins, Paul B. ^{[15
]}

Blake-Haskins, John A. ^{[15
]}

Segal, Neil H. ^{[16
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[4] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA

[5] Georgia Regent Univ, GRU Canc Ctr, Agusta, MD USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[8] Leuven Canc Inst, Leuven, Belgium

[9] Angeles Clin & Res Inst, Los Angeles, CA USA

[10] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[11] Mt Sinai Med Ctr, New York, NY 10029 USA

[12] Univ Hosp Siena, Siena, Italy

[13] Mary Crowley Canc Res Ctr, Dallas, TX USA

[14] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[15] Medlmmune, Gaithersburg, MD USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 01期

关键词：

D O I：

10.1158/2326-6074.CRICIMTEATIAACR15-A047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A047

引用

页数：2

共 50 条

[1] Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
Rizvi, Naiyer A.
Brahmer, Julie R.
Ou, Sai-Hong Ignatius
Segal, Neil Howard
Khleif, Samir
Hwu, Wen-Jen
Gutierrez, Martin
Schoffski, Patrick
Hamid, Omid
Weiss, Jared
Lutzky, Jose
Maio, Michele
Nemunaitis, John J.
Jaeger, Dirk
Balmanoukian, Ani Sarkis
Rebelatto, Marlon
Steele, Keith
Li, Xia
Blake-Haskins, John A.
Antonia, Scott Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).
Tatipalli, Manasa
Song, Xuyang
Pak, Min
Chavez, Carlos
Liang, Meina
Lu, Hong
Schwickart, Martin
Karakunnel, Joyson Joseph
Robbins, Paul B.
Jin, Xiaoping
Gupta, Ashok Kumar
Roskos, Lorin
Narwal, Rajesh
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Massard, Christophe
Gordon, Michael S.
Sharma, Sunil
Rafii, Saeed
Wainberg, Zev A.
Luke, Jason
Curiel, Tyler J.
Colon-Otero, Gerardo
Hamid, Omid
Sanborn, Rachel E.
O'Donnell, Peter H.
Drakaki, Alexandra
Tan, Winston
Kurland, John F.
Rebelatto, Marlon C.
Jin, Xiaoping
Blake-Haskins, John A.
Gupta, Ashok
Segal, Neil H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) : 3119 - +
[4] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
Hamid, Omid
Chow, Laura Quan Man
Tavakkoli, Fatemeh
Marshall, Shannon
Gribbin, Matthew Joseph
Karakunnel, Joyson Joseph
Gray, Jhanelle Elaine
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Vecchiarelli, S.
D'Incecco, A.
Minuti, G.
Gallo, M.
De Luca, A.
Landi, L.
Bennati, C.
Spreafico, M.
D'Arcangelo, M.
Attilia, L.
Mazza, V.
Normanno, N.
Cappuzzo, F.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389
[6] Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC)
Vecchiarelli, S.
D'Incecco, A.
Gallo, M.
De Luca, A.
Minuti, G.
Landi, L.
Bennati, C.
Spreafico, M.
D'Arcangelo, M.
Attilia, L.
Mazza, V.
Normanno, N.
Cappuzzo, F.
ANNALS OF ONCOLOGY, 2017, 28
[7] Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)
McLaughlin, Joseph
Schalper, Kurt A.
Carvajal-Hausdorf, Daniel E.
Pelekanou, Vasiliki
Velcheti, Vamsidhar
Haack, Herbert
Silver, Matthew R.
Herbst, Roy
LoRusso, Patricia
Rimm, David L.
CANCER RESEARCH, 2015, 75
[8] Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer
Chang, Sam S.
JOURNAL OF UROLOGY, 2018, 199 (02): : 341 - 342
[9] Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
Iguchi, Haruo
Nogami, Naoyuki
Kozuki, Toshiyuki
Matsumoto, Toshihiko
Tamura, Kenji
Yamamoto, Noboru
Shimomura, Akihiko
Hoshino, Yuji
Michibata, Yoshiko
Nii, Masahiro
Fujiwara, Yutaka
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).
Creelan, Ben C.
Chow, Laura Q.
Kim, Dong-Wan
Kim, Sang-We
Yeh, Tammie
Karakunnel, Joyson Joseph
Gibbons, Don Lynn
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →